VitaNova Life Sciences (VNOV) Cash from Discontinued Operations (2017 - 2019)

VitaNova Life Sciences (VNOV) posted Cash from Discontinued Operations of 50.0 for Q2 2019, up 99.72% on a QoQ basis from 17649.0 in Q4 2017.

VitaNova Life Sciences (VNOV) Cash from Discontinued Operations (2017 - 2019) Analysis & Trends

VitaNova Life Sciences' Cash from Discontinued Operations history runs 2 years deep, the most recent figure standing at 50.0 for Q2 2019.

Quarterly Cash from Discontinued Operations changed N/A year-over-year to 50.0 in Q2 2019, while the trailing twelve-month figure through Apr 2020 was 50.0 (changed N/A YoY) and the FY2019 annual result came in at 57054.0, up 840.96% from the prior year.
Cash from Discontinued Operations was 50.0 for Q2 2019 at VitaNova Life Sciences, up from 17649.0 in the prior quarter.
Across five years, Cash from Discontinued Operations topped out at 50.0 in Q2 2019 and bottomed at 17649.0 in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Discontinued Operations (Qtr)
1	Mckesson	105.15 Bn	101.18 Bn	4.04 Bn	-
2	Cencora	60.58 Bn	58.40 Bn	3.59 Bn	-
3	Cardinal Health	53.81 Bn	49.87 Bn	2.50 Bn	-
4	Henry Schein	9.71 Bn	9.57 Bn	1.07 Bn	-
5	Akso Health	3.28 Bn	3.28 Bn	-	-
6	111	651.73 Mn	572.63 Mn	23.58 Mn	-
7	Accendra Health	248.02 Mn	-88.86 Mn	278.03 Mn	-
8	Edap Tms	230.14 Mn	215.14 Mn	8.15 Mn	-
9	VitaNova Life Sciences	11.51 Mn	11.01 Mn	316,343.00	-
10	Cosmos Health	9.57 Mn	7.41 Mn	1.38 Mn	-

Download Data